Since becoming interim CEO 0n 11/21/2023 Dr. J has
Post# of 148109
(Total Views: 716)
Posted On: 07/11/2024 8:13:08 AM
Since becoming interim CEO 0n 11/21/2023 Dr. J has:
01/29/2024 Appointed Mitchell Cohen interim CFO
02/01/2024 Submitted clinical protocol to FDA and initiation of preclinical study in
gliobastoma
02/29/22024 Announced FDA has lifted clinical hold
06/27/2024 Announced start of preclinical MASH study
07/092024 Announced settlement with Amarex
This list is only those items PR'd on the Cytodyn website. There was no hype or hint as to these events. We can assume that work continues on a number of other initiatives. We won't hear about them until they are solidly, statistically accomplished.
All of this in less than 8 months. Fixing the foundation of this company is going to take more time. However, real work is being completed without exaggeration. Can we agree that this is a good start?
01/29/2024 Appointed Mitchell Cohen interim CFO
02/01/2024 Submitted clinical protocol to FDA and initiation of preclinical study in
gliobastoma
02/29/22024 Announced FDA has lifted clinical hold
06/27/2024 Announced start of preclinical MASH study
07/092024 Announced settlement with Amarex
This list is only those items PR'd on the Cytodyn website. There was no hype or hint as to these events. We can assume that work continues on a number of other initiatives. We won't hear about them until they are solidly, statistically accomplished.
All of this in less than 8 months. Fixing the foundation of this company is going to take more time. However, real work is being completed without exaggeration. Can we agree that this is a good start?
(38)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼